Live feed16:01:00·816dPRReleasevia QuantisnowBristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's DiseaseByQuantisnow·Wall Street's wire, on your screen.BMY· Bristol-Myers Squibb CompanyHealth Care
